ADAGENE PRESENTS INTERIM MONOTHERAPY DATA AT ESMO 2022

KUALA LUMPUR, Sept 12 (Bernama) -- Adagene Inc (Adagene), a company transforming the discovery and development of novel antibody-based therapies, has announced the publication of data showing the best-in-class potential of ADG126, a masked, anti-CTLA-4 SAFEbody®.

According to a statement, interim results from the Phase 1 portion of an ongoing Phase 1b/2 trial of ADG126 are being presented at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris, Sept 9 – 13, 2022.

The poster, titled “Phase 1 Results Demonstrate Highly Differentiated Safety and PK Profile of ADG126, a Masked anti-CTLA-4 SAFEbody® in Patients with Advanced Solid Tumors,” reviewed data from the first-in-human, open label, phase 1 dose-escalation and dose expansion.

The poster reports data on 26 patients with advanced metastatic solid tumours, the majority (58 per cent) of whom received three or more lines of prior therapies and nearly half (42 per cent) of whom progressed from prior immuno-oncology (IO) therapy.

Key findings include ADG126 monotherapy showed an unprecedented clinical safety profile at dosing levels up to 20 mg/kg when administered to this heavily pretreated patient population once every three weeks.

In addition, ADG126 plasma pharmacokinetics (PK) were approximately linear and activated ADG126 accumulated steadily during repeat dosing across different dose levels.

Trials evaluating the combination of ADG126 and anti-PD-1 therapies are ongoing in patients with advanced, metastatic tumours in the US, China and Asia Pacific (APAC), evaluating optimised doses of ADG126 in targeted tumours.

More details at https://investor.adagene.com.

-- BERNAMA